JP2015526487A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526487A5
JP2015526487A5 JP2015528857A JP2015528857A JP2015526487A5 JP 2015526487 A5 JP2015526487 A5 JP 2015526487A5 JP 2015528857 A JP2015528857 A JP 2015528857A JP 2015528857 A JP2015528857 A JP 2015528857A JP 2015526487 A5 JP2015526487 A5 JP 2015526487A5
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
pharmaceutically acceptable
mesomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015528857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526487A (ja
JP6262733B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2013/082273 external-priority patent/WO2014036897A1/zh
Publication of JP2015526487A publication Critical patent/JP2015526487A/ja
Publication of JP2015526487A5 publication Critical patent/JP2015526487A5/ja
Application granted granted Critical
Publication of JP6262733B2 publication Critical patent/JP6262733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015528857A 2012-09-04 2013-08-26 イミダゾリン誘導体、その製造法、およびそれらの医薬への適用 Active JP6262733B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210323870.3 2012-09-04
CN201210323870 2012-09-04
PCT/CN2013/082273 WO2014036897A1 (zh) 2012-09-04 2013-08-26 咪唑啉类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2015526487A JP2015526487A (ja) 2015-09-10
JP2015526487A5 true JP2015526487A5 (https=) 2017-12-21
JP6262733B2 JP6262733B2 (ja) 2018-01-17

Family

ID=50236528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528857A Active JP6262733B2 (ja) 2012-09-04 2013-08-26 イミダゾリン誘導体、その製造法、およびそれらの医薬への適用

Country Status (22)

Country Link
US (2) US9586947B2 (https=)
EP (1) EP2894151B1 (https=)
JP (1) JP6262733B2 (https=)
KR (1) KR102189940B1 (https=)
CN (1) CN103958480B (https=)
AU (1) AU2013312587B2 (https=)
BR (1) BR112015004637B1 (https=)
CA (1) CA2883545C (https=)
CY (1) CY1123649T1 (https=)
DK (1) DK2894151T3 (https=)
ES (1) ES2835248T3 (https=)
HR (1) HRP20202050T1 (https=)
HU (1) HUE052904T2 (https=)
LT (1) LT2894151T (https=)
MX (1) MX368844B (https=)
PT (1) PT2894151T (https=)
RS (1) RS61242B1 (https=)
RU (1) RU2639145C2 (https=)
SI (1) SI2894151T1 (https=)
SM (1) SMT202000672T1 (https=)
TW (1) TWI617546B (https=)
WO (1) WO2014036897A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036897A1 (zh) * 2012-09-04 2014-03-13 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
BR112017028269A2 (pt) * 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
CN106518773A (zh) * 2015-09-10 2017-03-22 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的结晶形式及其制备方法
RS60448B1 (sr) * 2015-09-10 2020-07-31 Jiangsu Hengrui Medicine Co Kristalni oblik inhibitora receptora androgena i postupak njegovog dobijanja
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
CA3014088A1 (en) * 2016-02-19 2017-08-24 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing imidazoline derivative
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
CN110167556A (zh) * 2016-07-08 2019-08-23 詹森药业有限公司 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂
CA3053805C (en) * 2017-02-13 2020-06-30 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
CN112174895B (zh) * 2017-12-13 2022-06-21 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的晶型及其制备方法
CN110684046B (zh) * 2018-07-06 2023-05-12 江苏恒瑞医药股份有限公司 一种新的咪唑啉类衍生物的制备方法
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
CR20210175A (es) 2018-09-18 2021-06-01 Nikang Therapeutics Inc Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
TW202029961A (zh) * 2018-10-22 2020-08-16 大陸商江蘇恒瑞醫藥股份有限公司 Ar拮抗劑聯合parp抑制劑在製備治療前列腺癌的藥物中的用途
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
CN113929628A (zh) * 2020-06-29 2022-01-14 江苏恒瑞医药股份有限公司 一种咪唑啉衍生物的制备方法
CN113024513A (zh) * 2021-03-22 2021-06-25 中国药科大学 新型雄激素受体降解剂、制备方法和医药用途
CN117327019A (zh) * 2022-06-23 2024-01-02 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂的应用
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途
CN118993935B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 咪唑啉衍生物或其盐的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
KR100927304B1 (ko) 2001-12-27 2009-11-18 다이이찌 세이야꾸 가부시기가이샤 β-아밀로이드 단백 생산·분비 저해제
AU2003279442A1 (en) * 2002-10-04 2004-04-23 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
US8470829B2 (en) * 2004-09-09 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Imidazolidine derivative and use thereof
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
NZ564223A (en) * 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
MX2011008452A (es) 2009-02-10 2011-12-16 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
US8710086B2 (en) * 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
US8450374B2 (en) 2009-06-29 2013-05-28 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
WO2011037795A1 (en) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US8916553B2 (en) 2010-07-26 2014-12-23 Bristol-Myers Squibb Company Sulfonamide compounds useful as CYP17 inhibitors
WO2012050868A1 (en) * 2010-09-28 2012-04-19 Georgia Tech Research Corporation Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof
CN103619171B (zh) 2010-11-03 2015-11-25 陶氏益农公司 杀虫组合物和与其相关的方法
EP2683694B1 (en) 2011-03-10 2016-04-27 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
WO2014036897A1 (zh) * 2012-09-04 2014-03-13 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用

Similar Documents

Publication Publication Date Title
JP2015526487A5 (https=)
RU2015110122A (ru) Производные имидазолина, способы их получения и их применение в медицине
TWI674258B (zh) Dna烷化劑
WO2017195216A4 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
CN110582483A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JP2007509116A5 (https=)
JP2015531773A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2013518106A5 (https=)
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1
JP2014185188A (ja) フェニルおよびベンゾジオキシニル置換インダゾール誘導体
CA2727378A1 (en) New co-crystal compound of rivaroxaban and malonic acid
IL228072A (en) Quinazoline compound is converted to alkyl and methods of use
JP2018527328A (ja) 置換3−(3−アニリノ−1−シクロヘキシル−1h−ベンズイミダゾール−5−イル)プロパン酸誘導体を調製する方法
JP2013521301A5 (https=)
CA3050239A1 (en) Pyrimidine compound and pharmaceutical use thereof
WO2014031755A1 (en) Fendiline derivatives and methods of use thereof
JP2019535825A5 (https=)
AU2015367540B2 (en) Substituted Pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
JP2017536342A5 (https=)
RU2012126112A (ru) Соединение, некоторые его новые формы, фармацевтические композиции на его основе и способы получения и применения
JP2009531363A5 (https=)
JP5575357B2 (ja) 組織因子産生抑制剤
AU2022224918A1 (en) Novel pyrazole derivatives
JP2018516873A5 (https=)
RU2013125756A (ru) Твердые формы (s)-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропановой кислоты